Product Description
Prucalopride, a first-in-class dihydrobenzofuran-carboxamide derivative, is a potent, selective and specific serotonin 5-HT(4) receptor agonist with enterokinetic properties. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/19911858/)
Mechanisms of Action: 5-HT4 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: Constipation
Known Adverse Events: Abdominal Pain | Dizziness | Headache | Pain Unspecified | Diarrhea | Flatulence
Company: Movetis
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Constipation
Phase 2: Colorectal Cancer|Diverticulitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2022-003221-22 | P3 |
Completed |
Constipation |
2023-08-25 |
|
| 2018-002192-18 | P2 |
Active, not recruiting |
Diverticulitis|Constipation|Colorectal Cancer |
2018-11-14 |